Literature DB >> 28933293

MicroRNAs in Atrial Fibrillation.

Alexandros Briasoulis1, Shikha Sharma2, Tesfaye Telila1, Sagar Mallikethi-Reddy1, Nikolaos Papageorgiou3, Evangelos Oikonomou3, Dimitris Tousoulis3.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs, involved in regulation of post-transcriptional gene expression. They exert key role not only in physiology and normal development of the cardiovascular system but also in cardiovascular disease development and progression. Recent animal and human studies of tissue specific miRNAs have suggested a role in structural and electrical remodeling in atrial fibrillation (AF). Their emerging role as biomarkers and potential therapeutic targets in patients with AF is discussed in this review. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  atrial fibrillation; biomarkers; cardiovascular disease; miRNAs; remodelling; small non-coding RNA.

Mesh：

Substances：

Year:  2019        PMID： 28933293     DOI： 10.2174/0929867324666170920151024

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  8 in total

1.  MicroRNAs sequencing of plasma exosomes derived from patients with atrial fibrillation: miR-124-3p promotes cardiac fibroblast activation and proliferation by regulating AXIN1.

Authors:  Pengju Zhu; Huilin Li; An Zhang; Zhan Li; Yong Zhang; Manyi Ren; Yujiao Zhang; Yinglong Hou
Journal:  J Physiol Biochem       Date:  2021-09-08       Impact factor: 4.158

2.  MicroRNA-205-5p plays a suppressive role in the high-fat diet-induced atrial fibrosis through regulation of the EHMT2/IGFBP3 axis.

Authors:  Zezhou Xiao; Yu Xie; Fangze Huang; Jie Yang; Ximao Liu; Xuefeng Lin; Peng Zhu; Shaoyi Zheng
Journal:  Genes Nutr       Date:  2022-07-20       Impact factor: 4.423

Review 3.  MicroRNAs in hypertrophic cardiomyopathy: pathogenesis, diagnosis, treatment potential and roles as clinical biomarkers.

Authors:  Fanyan Luo; Wei Liu; Haisong Bu
Journal:  Heart Fail Rev       Date:  2022-03-25       Impact factor: 4.654

4.  miR-29b ameliorates atrial fibrosis in rats with atrial fibrillation by targeting TGFβRΙ and inhibiting the activation of Smad-2/3 pathway.

Authors:  Xinyuan Han; Shunda Wang; Zhijun Yong; Xueting Zhang; Xuanqi Wang
Journal:  J Bioenerg Biomembr       Date:  2022-03-24       Impact factor: 3.853

Review 5.  The Therapeutic Potential of MicroRNAs in Atrial Fibrillation.

Authors:  Xiaona Xu; Zhiqiang Zhao; Guangping Li
Journal:  Mediators Inflamm       Date:  2020-03-12       Impact factor: 4.711

6.  Identification of a Diagnostic Set of Endomyocardial Biopsy microRNAs for Acute Cellular Rejection Diagnostics in Patients after Heart Transplantation Using Next-Generation Sequencing.

Authors:  Tereza Nováková; Táňa Macháčková; Jan Novák; Petr Hude; Július Godava; Víta Žampachová; Jan Oppelt; Filip Zlámal; Petr Němec; Helena Bedáňová; Ondřej Slabý; Julie Bienertová-Vašků; Lenka Špinarová; Jan Krejčí
Journal:  Cells       Date:  2019-11-06       Impact factor: 6.600

7.  miR‑101a‑3p overexpression prevents acetylcholine‑CaCl2‑induced atrial fibrillation in rats via reduction of atrial tissue fibrosis, involving inhibition of EZH2.

Authors:  Jing Zhu; Ning Zhu; Jian Xu
Journal:  Mol Med Rep       Date:  2021-08-26       Impact factor: 2.952

8.  Relationship between Serum miR-106 and MYL4 Levels and the Prevalence, Risk Stratification, and Prognosis of Atrial Fibrillation.

Authors:  Yanfeng Liu; Haiwen Zhou; Yu Tao; Zhicheng Xu; Hengli Lai
Journal:  J Immunol Res       Date:  2022-07-14       Impact factor: 4.493
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.